Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Immunotherapy
Immunotherapy
Urelumab Safe and Active as Monotherapy and in Combination with Nivolumab in Several Types of Cancer
By
Walter Alexander
Immunotherapy
,
Personalized Medicine
April 2017, Vol 8, No 2
National Harbor, MD—The investigational CD137 agonist urelumab, given as monotherapy and in combination with the anti–PD-1 monoclonal antibody nivolumab, demonstrated safety and, in some patients with hematologic and solid tumor malignancies, promising antitumor activity, according to results of 2 early-phase studies presented at the 2016 Society for Immunotherapy of Cancer annual meeting.
Read Article
Maximizing the Potential of Immunotherapy the Focus of Cancer Moonshot 2020
By
Wayne Kuznar
Immunotherapy
,
Personalized Medicine
December 2016, Vol 7, No 11
Washington, DC—The Cancer Moonshot 2020 program is exploring a new paradigm in cancer care by bringing clinical trials focused on immunotherapy to community and academic practices. This privately funded initiative seeks to conduct phase 2 clinical trials within the next 36 months in 20,000 patients with >20 tumor types at all stages of cancer, said Gary Palmer, MD, JD, MPH, Chief Medical Officer, President, GPS Operations, NantHealth, Culver City, CA, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Immunotherapies Changing the Treatment Landscape of Advanced Cancer Care
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
October 2016, Vol 7, No 9
Read Article
Immunotherapy Moving into Prime Time
By
Nick Bryant
Immunotherapy
,
Personalized Medicine
October 2016, Vol 7, No 9
Read Article
Checkpoint Inhibitors in Lymphoma: A New Universe
By
Phoebe Starr
Hematologic Malignancies
,
Immunotherapy
,
Lymphoma
,
Personalized Medicine
February 2016, Vol 7, No 1
Immunotherapy is generating great excitement in melanoma and non-small-cell lung cancer (NSCLC). The FDA approvals of checkpoint inhibitors in these tumor types, as well as encouraging preliminary results in other solid tumors, have paved the way for studying these therapies in hematologic cancers.
Read Article
Atezolizumab: Another Immunotherapy for Lung Cancer?
By
Phoebe Starr
Emerging Therapies
,
Immunotherapy
,
Personalized Medicine
October 2015, Vol 6, No 9
Vienna, Austria—Immunotherapy is poised to become a game changer for patients with non–small-cell lung cancer (NSCLC).
Read Article
Immunotherapies Steal the Show at ASCO 2015
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
September 2015, Vol 6, No 8
Chicago, IL—Oncologists looking to learn about immunotherapy did not have to go very far at the 2015 American Society of Clinical Oncology meeting. Many of the highest-impact presentations this year, including a plenary session, the Karnofsky Award, and the Science of Oncology Award, focused on cancer therapy’s most exciting field.
Read Article
Immunotherapy Makes Headwinds into Liver Cancer
By
Wayne Kuznar
ASCO 2015 Highlights
,
Immunotherapy
,
ASCO
June 2015, Vol 6, No 5
Chicago, IL—Immunotherapy with nivolumab (Opdivo) resulted in durable responses and promising overall survival (OS) in a dose-escalation and expansion trial of patients with advanced liver cancer. The 12-month OS rate exceeded 60% in patients in whom sorafenib (Nexavar) had failed, and responses occurred in patients with the hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, reported Anthony B. El-Khoueiry, MD, Assistant Professor of Clinical Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, at the 2015 American Society of Clinical Oncology (ASCO) meeting.
Read Article
Immunotherapy Vaccine Prolongs Recurrence-Free Survival in Advanced Ovarian Cancer
By
Alice Goodman
Gynecologic Oncology Highlights
,
Immunotherapy
April 2015, Vol 6, No 3
Chicago, IL—Immunotherapy holds promise for the maintenance treatment of late-stage ovarian cancer, according to results of a phase 2 clinical trial. The vaccine, made from the patient’s own tumor cells, was able to prolong recurrence-free survival compared with standard of care.
Read Article
PD-1 Monoclonal Antibodies Usher in the Era of Immunotherapy in Oncology
By
Dana Butler
Immunotherapy
,
Personalized Medicine
September 2014, Vol 5, No 7
Oncologists’ excitement about the promise of immunotherapy is about to be tested in clinical practice, with the recent FDA approval of pembrolizumab (Kytruda; Merck), the first anti–programmed death receptor-1 (PD-1) monoclonal antibody
Read Article
Page 5 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma